Angiogenesis

- History of Angiogenesis
- Angiogenesis and Vascular Remodeling: Biology and Architecture of the Vasculature
- Endothelial Cell Activation
- Pericytes, the Mural Cells of the Microvascular System
- Matrix Metalloproteinases and Their Endogenous Inhibitors
- Integrins in Angiogenesis
- Fibroblast Growth Factor-2
- Vascular Permeability Factor/Vascular Endothelial Growth Factor
- Platelet-derived Growth Factor
- Angiopoietins and Tie Receptors
- Basement Membrane-derived Inhibitors of Angiogenesis
- Endostatin and Angiostatin
- Thrombospondins
- Overview of Angiogenesis during Tumor Growth
- Hypoxic Regulation of Angiogenesis by HIF-1
- Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2
- Nitric Oxide in Tumor Angiogenesis
- VEGF Signal Transduction in Angiogenesis
- Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis
- Immune Cells and Inflammatory Mediators as Regulators of Angiogenesis
- Contribution of Endothelial Progenitor Cells to the Angiogenic Process
- The Cancer Stem Cell Model
- Targeting the Tumor Microenvironment (Stroma)
- Normalization of Tumor Vasculature and Microenvironment
- Targeted Drug Delivery to the Tumor Neovasculature
- Models for Angiogenesis
- Surrogates for Clinical Development
- Imaging of Angiogenesis
- Tumor Endothelial Markers
- Overview and Clinical Applications of VEGF-A
- Protein Tyrosine Kinase as Antiangiogenic Agents
- Therapeutic Strategies that Target the HIF System
- The Clinical Utility of Bevacizumab
- Development of Thalidomide and its IMiD Derivatives
- TNP-470: The Resurrection of One of the First Angiogenesis Inhibitors
- Clinical Development of VEGF Trap
- Recent Advances in Angiogenesis Drug Development
- Combination of Angiogenic Therapy with other Anticancer Therapies
- Immunotherapy of Angiogenesis with DNA Vaccines
- Challenges of Antiangiogenic Therapy of Tumors
- Pharmacogenetics of Antiangiogenic Therapy
- Angiogenesis in the Central Nervous System
-

From the reviews: